Molbio Diagnostics Limited (MOLBIO)

Loading page…

Molbio Diagnostics Limited (MOLBIO) · mywealthgrid

About

Molbio Diagnostics Limited operates in Medical Equipment & Supplies within the Healthcare sector.

Face value: ₹1

Market cap

₹17,431 Cr

P/E

120.1×

P/B

14.6×

Dividend yield

ROE

16.2%

ROCE

23.7%

Debt / equity

0.35

OPM

25.7%

EPS (TTM)

₹12.9

Book value

₹103.7

52-week high

—

52-week low

—

30 historical price candles were omitted because the exchange source has not been verified.

₹1,513.1+20.5%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 25.7%
+Comfortable interest coverage of 12.8×

Cons

−Low return on equity of 9.8% (3-yr avg)
−Expensive at 120.1× trailing earnings
−Trading at 14.6× book value

Research score

Structured signal from quality, growth, valuation and momentum.

34/100

Business quality: 69
Valuation: 0

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024	Mar 2025
	332	837	1,020
	289	602	758
Operating profit (EBITDA)	43	234	262
OPM %	13%	28%	25.7%
Depreciation	32	41	45
Interest	7	14	18
	5	57	19
Profit before tax	10	130	194
Tax	13	46	56
Tax %	136.2%	35.6%	28.7%
	-3	84	139
PAT margin %	-1%	10%	13.6%
EPS (₹)	—	—	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	2	2	2	11
Reserves	719	821	966	1,158
Minority interest	16	5	—	139
	108	175	123	413
	188	218	370	427
Total equity & liabilities	1,034	1,221	1,462	2,148
	267	242	261	481
CWIP	0	2	27	11
Investments	0	6	46	6
	767	971	1,128	1,650
Total assets	1,034	1,221	1,462	2,148

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 22%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 66%

Return on equity

7 years: —
5 years: —
3 years: 8%
Last year: 14%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated figures

Ratio	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	—	—	—
EBITDA margin %	13%	28%	25.7%
EBIT margin %	3.4%	23.1%	21.3%
PAT margin %	-1%	10%	13.6%
Working capital
Receivable days	207	186	97
Inventory days	438	191	210
Payable days	108	—	—
NWC days	537	—	—
Leverage
Current ratio	2.37	2.4	2.11
Debt to EBITDA	2.51	0.75	0.47
Debt to equity	0.15	0.21	0.13
Interest coverage	2.4	13.7	12.8
Asset turnover	0.32	0.69	0.7
Return ratios
Return on assets %	-0.3%	6.8%	9.5%
Return on capital employed %	2.1%	23.8%	23.7%
Return on equity %	-0.5%	10.1%	14.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2026
	41.29%
	1.51%
	16.35%
	0.02%
	40.83%
No. of shareholders	2,33,544

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Schemes holding

across 5 fund houses

Held by these funds

3.21%

of the company's equity

All mutual funds

2.25%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

no prior month

13 schemes · 5 fund houses

		Shares
Portfolio of Kotak Aggressive Hybrid Fund	Kotak Mahindra Mutual Fund	12 L	130.36	1.4%	1.042%	—
Portfolio of Kotak Contra Fund	Kotak Mahindra Mutual Fund	5.2 L	56.44	1.02%	0.451%	—
PHARMA FUND	Nippon India Mutual Fund	3.8 L	41.31	0.44%	0.33%	—
Portfolio of Kotak Healthcare Fund	Kotak Mahindra Mutual Fund	3.2 L	34.76	4.53%	0.278%	—
Portfolio of Kotak Large Cap Fund	Kotak Mahindra Mutual Fund	3 L	32.55	0.3%	0.26%	—
Quality Fund	ICICI Prudential Mutual Fund	1.86 L	20.19	0.94%	0.161%	—
Innovation Fund	Nippon India Mutual Fund	1.71 L	18.52	0.6%	0.148%	—
Exports and Services Fund	ICICI Prudential Mutual Fund	1.49 L	16.15	1.04%	0.129%	—

1–8 of 13

1 / 2

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results5 Sept 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

1 Oct 2026, 3:40 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Loading announcements…

Ratio	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	—	—	—
EBITDA margin %	13%	28%	25.7%
EBIT margin %	3.4%	23.1%	21.3%
PAT margin %	-1%	10%	13.6%
Working capital
Receivable days	207	186	97
Inventory days	438	191	210
Payable days	108	—	—
NWC days	537	—	—
Leverage
Current ratio	2.37	2.4	2.11
Debt to EBITDA	2.51	0.75	0.47
Debt to equity	0.15	0.21	0.13
Interest coverage	2.4	13.7	12.8
Asset turnover	0.32	0.69	0.7
Return ratios
Return on assets %	-0.3%	6.8%	9.5%
Return on capital employed %	2.1%	23.8%	23.7%
Return on equity %	-0.5%	10.1%	14.3%

16 deals · 17 Aug 2026 – 30 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Sept 2026	BUSINESS EXCELLENCE TRUST III	Bulk	BSE	Sell	23,28,996	₹1,315.01	₹306.27 Cr
30 Sept 2026	HDFC MUTUAL FUND	Bulk	BSE	Buy	23,00,000	₹1,315.00	₹302.45 Cr
23 Sept 2026	BUSINESS EXCELLENCE TRUST III	Bulk	BSE	Sell	29,96,798	₹1,315.00	₹394.08 Cr
23 Sept 2026	KOTAK MAHINDRA MUTUAL FUND	Bulk	BSE	Buy	27,50,000	₹1,315.00	₹361.63 Cr
16 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	5,91,823	₹1,288.60	₹76.26 Cr
16 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	5,90,709	₹1,288.14	₹76.09 Cr
11 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	12,33,175	₹1,565.79	₹193.09 Cr
11 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	12,28,332	₹1,566.94	₹192.47 Cr
11 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Buy	12,10,738	₹1,542.36	₹186.74 Cr
11 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Sell	11,88,458	₹1,552.02	₹184.45 Cr

1–10 of 16

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Molbio Diagnostics LimitedMOLBIOMOLBIO	₹17,431 Cr	₹17,844 Cr	₹1,020 Cr	₹262 Cr	25.7%	₹145 Cr	13.6%	23.7%	16.2%	—
Poly Medicure LimitedPOLYMEDPOLYMED	₹16,610 Cr	₹16,952 Cr	₹1,997 Cr	₹461 Cr	23.6%	₹315 Cr	17.1%	14.5%	11%	294
Fischer Medical Ventures LimitedFISCHERFISCHER	₹2,190 Cr	₹2,262 Cr	₹367 Cr	₹50 Cr	14%	₹30 Cr	10.1%	13.6%	8.6%	111
Tarsons Products LimitedTARSONSTARSONS	₹1,752 Cr	₹2,135 Cr	₹441 Cr	₹119 Cr	27.9%	₹11 Cr	3.4%	5%	2.3%	361
Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL	₹1,066 Cr	₹1,066 Cr	₹287 Cr	₹46 Cr	15.6%	₹31 Cr	10.4%	14.7%	12.8%	109
Hemant Surgical Industries LtdHSILHSIL	₹885 Cr	—	₹232 Cr	₹23 Cr	10%	₹18 Cr	7.9%	—	—	—
Fabtech Technologies LimitedFABTECHFABTECH	₹632 Cr	₹675 Cr	₹418 Cr	₹45 Cr	8.5%	₹49 Cr	9.3%	15.5%	12.9%	55
Prevest Denpro LtdPREVESTPREVEST	₹452 Cr	—	₹72 Cr	₹25 Cr	34.4%	₹20 Cr	28.5%	—	—	—
Nureca LimitedNURECANURECA	₹332 Cr	₹333 Cr	₹153 Cr	₹4 Cr	0.1%	₹4 Cr	1.4%	3.3%	1.1%	186
Earkart LtdEARKARTEARKART	₹179 Cr	₹179 Cr	₹54 Cr	₹8 Cr	15.5%	₹5 Cr	9.1%	12.1%	7.7%	243
Choksi Asia LtdCHOKSICHOKSI	₹117 Cr	₹119 Cr	₹11 Cr	₹-2 Cr	13.8%	₹2 Cr	10.8%	18.9%	13.5%	142
Shree Pacetronix LtdSHREEPACSHREEPAC	₹68 Cr	₹71 Cr	₹8 Cr	₹1 Cr	23.5%	₹0 Cr	14%	27.4%	18.9%	385

Date	Category	Subject	Filing
1 Oct 2026, 3:40 pm	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	PDF
1 Oct 2026, 10:20 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	PDF
28 Sept 2026, 3:41 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
17 Sept 2026, 3:23 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
12 Sept 2026, 10:14 am	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
9 Sept 2026, 12:17 pm	Company Update General	Change Of Corporate Identification Number (CIN) Of The Company.	PDF
8 Sept 2026, 6:17 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
8 Sept 2026, 2:57 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF

Molbio Diagnostics Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

1

Announcements

1

Not in the F&O segment

Announcements

Offer and rights documents

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Molbio Diagnostics Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Board meetings1

Not in the F&O segment

Announcements

Quarterly record

Offer and rights documents

Investor Presentation and earnings call

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1